ALKEM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | ALKEM | Market Cap | 68,392 Cr. | Current Price | 5,720 ₹ | High / Low | 5,934 ₹ |
| Stock P/E | 30.6 | Book Value | 1,143 ₹ | Dividend Yield | 0.78 % | ROCE | 19.5 % |
| ROE | 19.9 % | Face Value | 2.00 ₹ | DMA 50 | 5,654 ₹ | DMA 200 | 5,433 ₹ |
| Chg in FII Hold | 0.50 % | Chg in DII Hold | -0.39 % | PAT Qtr | 724 Cr. | PAT Prev Qtr | 610 Cr. |
| RSI | 36.7 | MACD | -7.70 | Volume | 1,30,491 | Avg Vol 1Wk | 1,11,046 |
| Low price | 4,492 ₹ | High price | 5,934 ₹ | PEG Ratio | 2.20 | Debt to equity | 0.06 |
| 52w Index | 85.2 % | Qtr Profit Var | 12.8 % | EPS | 204 ₹ | Industry PE | 28.2 |
📊 Financials: ALKEM demonstrates strong fundamentals with ROCE at 19.5% and ROE at 19.9%, reflecting solid capital efficiency. Quarterly PAT improved from ₹610 Cr. to ₹724 Cr., showing healthy earnings growth. Debt-to-equity is very low at 0.06, indicating a nearly debt-free balance sheet. EPS of ₹204 is robust, supporting long-term earnings visibility.
💹 Valuation: The stock trades at a P/E of 30.6, slightly above the industry average of 28.2, suggesting mild overvaluation. P/B ratio is ~5.0 (5720/1143), which is moderately expensive. PEG ratio of 2.20 highlights valuations stretched relative to growth. Dividend yield of 0.78% provides modest income support.
🏢 Business Model & Competitive Advantage: ALKEM operates in pharmaceuticals, focusing on branded generics and specialty drugs. Its competitive advantage lies in strong domestic presence, diversified portfolio, and efficient capital utilization. The company’s low debt and consistent profitability strengthen its long-term outlook.
📈 Entry Zone: Technicals show RSI at 36.7 (near oversold) and MACD negative, with price below DMA 50 & 200. Accumulation is favorable near ₹5,400–5,600. Long-term investors may hold, as fundamentals remain strong and industry demand supports growth.
Positive
- Strong ROCE (19.5%) and ROE (19.9%).
- Debt-to-equity ratio of 0.06 shows financial stability.
- Quarterly PAT growth from ₹610 Cr. to ₹724 Cr.
Limitation
- P/E ratio (30.6) slightly above industry average (28.2).
- P/B ratio (~5.0) indicates moderately expensive valuation.
- Dividend yield of 0.78% is modest.
Company Negative News
- Stock trading below DMA 200, reflecting weak momentum.
- DII holdings decreased by -0.39%, showing reduced domestic institutional confidence.
Company Positive News
- FII holdings increased by 0.50%, reflecting foreign investor interest.
- Quarterly PAT growth highlights operational improvement.
Industry
- Pharmaceutical sector benefits from global demand for generics and specialty drugs.
- Industry P/E at 28.2 is slightly lower than ALKEM, showing sector-wide value opportunities.
- Government healthcare initiatives and export demand support long-term